Late-breaking and deferred publication abstractsHead and neck cancer, excluding thyroidLBA8_PR - KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Head and neck cancer, excluding thyroid
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2018 THE AUTHORS. Published by Elsevier Ltd. All rights reserved.